Linvoseltamab
Bispecific B Cell Maturation Antigen-directed CD3 T Cell Engager — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Also known as: linvoseltamab-gcpt, lynozyfic, REGN5458
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Linvoseltamab is a drug in the Bispecific B Cell Maturation Antigen-directed CD3 T Cell Engager class catalogued in DrugCentral. It was first approved by the EMA in 2025. Its mechanism of action is classified as B Cell Maturation Antigen-directed Antibody Interactions, CD3 Receptor Agonists and CD3-directed Antibody Interactions. DrugCentral lists 2 molecular targets, including CD3E|CD3G|CD3D and TNFRSF17. Recorded indications include Relapsed or refractory multiple myeloma.
- Drug class: Bispecific B Cell Maturation Antigen-directed CD3 T Cell Engager.
- Mechanism of action: B Cell Maturation Antigen-directed Antibody Interactions; CD3 Receptor Agonists; CD3-directed Antibody Interactions.
- Molecular targets: CD3E|CD3G|CD3D and TNFRSF17 (2 listed in DrugCentral).
- Indications: Relapsed or refractory multiple myeloma.
- ATC code: L01FX37 (Other monoclonal antibodies and antibody drug conjugates).
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Relapsed or refractory multiple myeloma
Mechanism & targets
| Mechanism of action (MoA) | B Cell Maturation Antigen-directed Antibody Interactions; CD3 Receptor Agonists; CD3-directed Antibody Interactions |
|---|---|
| Established pharmacologic class | Bispecific B Cell Maturation Antigen-directed CD3 T Cell Engager |
Molecular targets (2)
| Target | Gene | Action | Activity |
|---|---|---|---|
| T-cell surface glycoprotein CD3 | CD3E|CD3G|CD3D | other | EC50 6.81 |
| Tumor necrosis factor receptor superfamily member 17 | TNFRSF17 | other | Kd 0.44 |
Regulatory approvals (2)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2025-07-02 | FDA | — | RENGENERON PHARMACEUTICALS, INC. | Yes |
| 2025-04-23 | EMA | — | Regeneron Ireland Designated Activity Company (DAC) |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
L01FX37 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES › Other monoclonal antibodies and antibody drug conjugates |
Chemical structure
| Molecular formula | — |
|---|---|
| Molecular weight | — |
| CAS number | — |
| InChIKey | — |
| PubChem CID | — |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Linvoseltamab used for?
DrugCentral lists the following indications for Linvoseltamab: Relapsed or refractory multiple myeloma.
How does Linvoseltamab work?
Linvoseltamab is classified as B Cell Maturation Antigen-directed Antibody Interactions, CD3 Receptor Agonists and CD3-directed Antibody Interactions; its molecular targets in DrugCentral include CD3E|CD3G|CD3D and TNFRSF17.
When was Linvoseltamab first approved?
Linvoseltamab was first approved by the EMA in 2025.
What drug class does Linvoseltamab belong to?
Linvoseltamab is in the Bispecific B Cell Maturation Antigen-directed CD3 T Cell Engager class.
Browse: all drugs starting with L · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 5777 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL5095373 — compound record and bioactivity
- FDA UNII M3CPC50MZS — substance identity
- DailyMed: FDA labels for Linvoseltamab — current prescribing information (label search)
- UniProt Q02223 (TNFRSF17) — target protein
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.